YouTube video by STAT

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with other conditions that cause them to struggle to stay awake.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.

YouTube video by STAT

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

STAT reviewed dozens of studies, interviewed chronic disease experts, and landed on three focus areas for Robert F. Kennedy Jr. to boost health.

How would you solve the chronic disease epidemic? Here's STAT's extensive new data analysis, and nine ways to tackle the problem.

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from

After health secretary RFK Jr.’s ‘radical transparency’ pledge, HHS has shuttered much of the agency's communications and FOIA operations.

HHS is set to cut 10,000 jobs and consolidate divisions — have you been affected? @statnews would like to hear from you.

The Trump administration has canceled funding for an ongoing 30-year, nationwide study tracking patients with prediabetes and diabetes, researchers said.

The White House has pulled the nomination of Dave Weldon as CDC director hours before heh was set to appear for his confirmation hearing.

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

HHS Secretary Robert F. Kennedy Jr. moved to rescind the longtime practice of giving the public a chance to comment on the health agency’s plans.

How much weight loss is too much? Pharma is pushing the limit with new obesity drugs.

The cuts hit the FDA's medical device center particularly hard, including reviewers and experts on AI-enabled medical technology.

The cuts are part of a purge of 5,200 probationary workers across federal health agencies that started Friday.

STAT is backing up and monitoring CDC data in real time: See what's changing.

Have you been affected by firings at federal health agencies? @statnews would like to hear from you.

Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.

The NIH said Friday night that it would slash support for indirect costs on all existing and future grants to 15%

The Trump administration on Friday said global malaria aid can restart, but it was unclear how quickly the money would start flowing again.

The FDA is always trying to staff up, and already struggles to fulfill some duties.

Two senators wrote to the FDA Friday about the Hims Super Bowl ad, which they said misleads patients about compounded weight loss drugs.

Eli Lilly's CEO says the company is considering offering more Zepbound doses in vials at lower cost.

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

In the debate over weight loss medications, the FDA appears to have shifted toward the importance of drugs.

Patrizia Cavazzoni, leader of the FDAs Center for Drug Evaluation and Research, is leaving the agency on Jan. 18

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

Medicare is already spending billions on drugs like Ozempic, and Biden recently proposed expanding access to obesity treatments.

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.

Novo Nordisk’s next-gen obesity drug led patients to lose substantial weight, but fell short of expectations.

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.

STAT's Readout LOUD podcast discusses Trump's pick for FDA chief and offers a year-end round of questions and predictions about biopharma in 2025.